NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGNX stock has increased by 16.5% and is now trading at $38.32. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($1.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.87) by $0.21. The biotechnology company earned $17.60 million during the quarter, compared to the consensus estimate of $17.99 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. The firm's revenue for the quarter was up 1855.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.89) EPS. View Regenxbio's earnings history.

6 brokers have issued 12 month price targets for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's share price to reach $70.00 in the next year. This suggests a possible upside of 82.7% from the stock's current price. View analysts' price targets for Regenxbio.

Headlines about RGNX stock have been trending extremely positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regenxbio earned a news impact score of 4.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutRegenxbio.

Regenxbio saw a drop in short interest in May. As of May 15th, there was short interest totaling 4,000,000 shares, a drop of 8.0% from the April 30th total of 4,350,000 shares. Based on an average daily trading volume, of 520,200 shares, the short-interest ratio is presently 7.7 days. Currently, 11.5% of the company's stock are short sold. View Regenxbio's Current Options Chain.

Some companies that are related to Regenxbio include Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC) and Fate Therapeutics (FATE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.56%), Redmile Group LLC (6.28%), State Street Corp (5.28%), JPMorgan Chase & Co. (4.04%), WS Management Lllp (1.71%) and UBS Group AG (1.68%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Carmignac Gestion, Perceptive Advisors LLC, WS Management Lllp, Morgan Stanley, Morgan Stanley, and WINTON GROUP Ltd. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, and Vittal Vasista. View insider buying and selling activity for Regenxbio.

RGNX stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, JPMorgan Chase & Co., Burrage Capital Management LLC, State Street Corp, First Manhattan Co., Assenagon Asset Management S.A., Foresite Capital Management II LLC, and Korea Investment CORP. View insider buying and selling activity for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $38.32.

Regenxbio has a market capitalization of $1.43 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]